Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus curvatus HY7601 is a probiotic bacterial strain, isolated from kimchi and developed by the South Korean company hy Co., Ltd. (formerly Korea Yakult). [3, 4, 5, 7] It is primarily researched for its benefits to metabolic health, often in a synergistic combination with *Lactobacillus plantarum* KY1032. [1, 2] Clinical and preclinical studies have shown that supplementation with HY7601 can reduce body weight, visceral fat, and waist circumference, and lower plasma triglycerides. [9] The proposed mechanism of action involves modulation of the gut microbiota, which in turn influences host metabolism. [5] Specifically, it has been shown to down-regulate pro-inflammatory genes in adipose tissue, up-regulate fatty acid oxidation-related genes in the liver, and inhibit adipogenesis. [5, 10] It may also play a role in neuroprotection, with preclinical studies suggesting it could delay the progression of Alzheimer's disease. [4] The strain has been granted New Dietary Ingredient (NDI) and self-affirmed Generally Recognized as Safe (GRAS) status in the United States, and has been approved by the Korean Ministry of Food and Drug Safety (MFDS) as a functional ingredient for helping to reduce body fat. [2, 3, 4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactobacillus curvatus HY7601.